Bio-Rad Laboratories, Inc. Class A Common Stock vs ZIM Integrated Shipping Services Ltd — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.61 (market cap $9.43B), while ZIM Integrated Shipping Services Ltd trades at $25.23 (market cap $2.96B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.2× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | ZIM | |
|---|---|---|
Market Cap | $9.43B | $2.96B |
Sector | Health | Industrials |
52-Week High | $356.25 | $29.27 |
52-Week Low | $241.71 | $12.44 |
Enterprise Value | $9.18B | $6.81B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
ZIM Integrated Shipping Services trades at $24.91, down 1.19% for the day, with a bearish technical outlook and mixed fundamental picture. The stock shows attractive valuation metrics including P/S of 0.47 and P/B of 0.77, but faces profitability challenges with a 1.56% net margin. Recent Q1 2026 earnings missed expectations, while Q2 results are anticipated amid merger uncertainty with Hapag-Lloyd.
The outlook remains cautious with analyst consensus evenly split between Hold and Sell ratings and a $16.75 price target well below current levels. Key risks include regulatory hurdles for the proposed merger, declining revenue projections, and volatile shipping rates. The company's strong cash position provides some downside protection, but near-term headwinds outweigh growth catalysts.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →